Hypercalcemia following discontinuation of denosumab therapy: A systematic review

Denosumab is a monoclonal antibody that has been approved to treat osteoporosis, skeletal metastasis, and giant cell tumor of bone in skeletally mature patients. Due to its potential adverse effects on normal bone growth, its use has not yet been approved in skeletally immature patients; however, th...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Keisuke Horiuchi, Eisuke Kobayashi, Tsukasa Mizuno, Michiro Susa, Kazuhiro Chiba
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Denosumab Hypercalcemia Adverse event Juvenile Discontinuation Rebound Diseases of the musculoskeletal system RC925-935
Acceso en línea:	https://doaj.org/article/fd67b69514304e609ca96a677fff2bf5
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:fd67b69514304e609ca96a677fff2bf5
record_format	dspace
spelling	oai:doaj.org-article:fd67b69514304e609ca96a677fff2bf52021-11-16T04:10:45ZHypercalcemia following discontinuation of denosumab therapy: A systematic review2352-187210.1016/j.bonr.2021.101148https://doaj.org/article/fd67b69514304e609ca96a677fff2bf52021-12-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2352187221004058https://doaj.org/toc/2352-1872Denosumab is a monoclonal antibody that has been approved to treat osteoporosis, skeletal metastasis, and giant cell tumor of bone in skeletally mature patients. Due to its potential adverse effects on normal bone growth, its use has not yet been approved in skeletally immature patients; however, the use of this agent in such patients with overt or dysregulated bone resorptive conditions has been explored in recent years. While most studies have proven the effectiveness of denosumab in controlling the progression of various disorders in skeletally immature patients, they have also revealed that refractory hypercalcemia often follows the discontinuation of denosumab treatment, raising a concern over the use of this agent in these patients. Thus, this study was designed to better understand the pathology of this condition through a systematic review of the published literature. Our analysis suggests that this condition has a potential male predisposition, that there is a correlation between the duration of denosumab treatment and patient age, and that this condition often occurs within 3 months after the last administration of denosumab in skeletally immature patients but is significantly less likely in adults. These results may further underscore that high bone formation and bone turnover rates are critically associated with hypercalcemia after the discontinuation of denosumab. In contrast, given that not all skeletally immature patients develop hypercalcemia, it is probable that other unidentified factors are involved in the pathology of this condition.Keisuke HoriuchiEisuke KobayashiTsukasa MizunoMichiro SusaKazuhiro ChibaElsevierarticleDenosumabHypercalcemiaAdverse eventJuvenileDiscontinuationReboundDiseases of the musculoskeletal systemRC925-935ENBone Reports, Vol 15, Iss , Pp 101148- (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Denosumab Hypercalcemia Adverse event Juvenile Discontinuation Rebound Diseases of the musculoskeletal system RC925-935
spellingShingle	Denosumab Hypercalcemia Adverse event Juvenile Discontinuation Rebound Diseases of the musculoskeletal system RC925-935 Keisuke Horiuchi Eisuke Kobayashi Tsukasa Mizuno Michiro Susa Kazuhiro Chiba Hypercalcemia following discontinuation of denosumab therapy: A systematic review
description	Denosumab is a monoclonal antibody that has been approved to treat osteoporosis, skeletal metastasis, and giant cell tumor of bone in skeletally mature patients. Due to its potential adverse effects on normal bone growth, its use has not yet been approved in skeletally immature patients; however, the use of this agent in such patients with overt or dysregulated bone resorptive conditions has been explored in recent years. While most studies have proven the effectiveness of denosumab in controlling the progression of various disorders in skeletally immature patients, they have also revealed that refractory hypercalcemia often follows the discontinuation of denosumab treatment, raising a concern over the use of this agent in these patients. Thus, this study was designed to better understand the pathology of this condition through a systematic review of the published literature. Our analysis suggests that this condition has a potential male predisposition, that there is a correlation between the duration of denosumab treatment and patient age, and that this condition often occurs within 3 months after the last administration of denosumab in skeletally immature patients but is significantly less likely in adults. These results may further underscore that high bone formation and bone turnover rates are critically associated with hypercalcemia after the discontinuation of denosumab. In contrast, given that not all skeletally immature patients develop hypercalcemia, it is probable that other unidentified factors are involved in the pathology of this condition.
format	article
author	Keisuke Horiuchi Eisuke Kobayashi Tsukasa Mizuno Michiro Susa Kazuhiro Chiba
author_facet	Keisuke Horiuchi Eisuke Kobayashi Tsukasa Mizuno Michiro Susa Kazuhiro Chiba
author_sort	Keisuke Horiuchi
title	Hypercalcemia following discontinuation of denosumab therapy: A systematic review
title_short	Hypercalcemia following discontinuation of denosumab therapy: A systematic review
title_full	Hypercalcemia following discontinuation of denosumab therapy: A systematic review
title_fullStr	Hypercalcemia following discontinuation of denosumab therapy: A systematic review
title_full_unstemmed	Hypercalcemia following discontinuation of denosumab therapy: A systematic review
title_sort	hypercalcemia following discontinuation of denosumab therapy: a systematic review
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/fd67b69514304e609ca96a677fff2bf5
work_keys_str_mv	AT keisukehoriuchi hypercalcemiafollowingdiscontinuationofdenosumabtherapyasystematicreview AT eisukekobayashi hypercalcemiafollowingdiscontinuationofdenosumabtherapyasystematicreview AT tsukasamizuno hypercalcemiafollowingdiscontinuationofdenosumabtherapyasystematicreview AT michirosusa hypercalcemiafollowingdiscontinuationofdenosumabtherapyasystematicreview AT kazuhirochiba hypercalcemiafollowingdiscontinuationofdenosumabtherapyasystematicreview
_version_	1718426763926700032

Hypercalcemia following discontinuation of denosumab therapy: A systematic review

Ejemplares similares